Frank Mottola - 25 Aug 2025 Form 4 Insider Report for SUPERNUS PHARMACEUTICALS, INC. (SUPN)

Role
SVP, Quality, GMP, Ops, IT
Signature
/s/ Timothy C. Dec, as attorney-in-fact
Issuer symbol
SUPN
Transactions as of
25 Aug 2025
Net transactions value
-$441,420
Form type
4
Filing time
27 Aug 2025, 16:59:36 UTC
Previous filing
07 Mar 2025
Next filing
15 Sep 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Mottola Frank SVP, Quality, GMP, Ops, IT C/O SUPERNUS PHARMACEUTICALS, INC.,, 9715 KEY WEST AVENUE, ROCKVILLE /s/ Timothy C. Dec, as attorney-in-fact 27 Aug 2025 0001804567

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SUPN Common Stock Options Exercise $181,720 +14,000 +90% $12.98 29,496 25 Aug 2025 Direct F1
transaction SUPN Common Stock Sale $623,140 -14,000 -47% $44.51 15,496 25 Aug 2025 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SUPN Employee Stock Option (Right to Buy) Options Exercise $0 -14,000 -100% $0.000000 0 25 Aug 2025 Common Stock 14,000 $12.98 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes an aggregate of 345 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan.
F2 The Reporting Person exercised the options indicated herein and sold the underlying shares prior to the expiration of such options on March 1, 2026.
F3 The option vests in four equal annual installments beginning on March 1, 2017.